Glomerular disease: looking beyond pathology

The National Institute of Diabetes and Digestive and Kidney Diseases-supported Kidney Research National Dialogue asked the scientific community to formulate and prioritize research objectives aimed at improved understanding of kidney function and disease progression. Over the past 2 years, 1600 part...

Full description

Saved in:
Bibliographic Details
Published inClinical journal of the American Society of Nephrology Vol. 9; no. 6; pp. 1138 - 1140
Main Authors Wiggins, Roger C, Alpers, Charles E, Holzman, Lawrence B, He, John C, Salant, David J, Chugh, Sumant S, Natarajan, Rama, Trachtman, Howard, Brasile, Lauren, Star, Robert A, Rys-Sikora, Krystyna E, Moxey-Mims, Marva M, Flessner, Michael F
Format Journal Article
LanguageEnglish
Published United States American Society of Nephrology 06.06.2014
Subjects
Autoantibodies
Biomedical Research
Endothelium, Vascular
Humans
Kidney Diseases - classification
Kidney Diseases - etiology
Kidney Diseases - therapy
Kidney Glomerulus - blood supply
Podocytes - cytology
Podocytes - metabolism
Precision Medicine
translational and clinical research
endothelium
glomerulosclerosis
inflammation
podocytes
GN
autoantibodies
nephrotic syndrome
Online AccessGet full text

Cover

More Information
Summary:The National Institute of Diabetes and Digestive and Kidney Diseases-supported Kidney Research National Dialogue asked the scientific community to formulate and prioritize research objectives aimed at improved understanding of kidney function and disease progression. Over the past 2 years, 1600 participants posted almost 300 ideas covering all areas of kidney disease. An overriding theme that evolved through these discussions is the need to move beyond pathology to take advantage of basic science and clinical research opportunities to improve diagnostic classification and therapeutic options for people with primary glomerular disease. High-priority research areas included focus on therapeutic targets in glomerular endothelium and podocytes, regenerating podocytes through developmental pathways, use of longitudinal phenotypically defined disease cohorts to improve classification schemes, identifying biomarkers, disease-specific therapeutics, autoantibody triggers, and changing the clinical research culture to promote participation in clinical trials. Together, these objectives provide a path forward for improving clinical outcomes of glomerular disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1555-9041
1555-905X
DOI:10.2215/CJN.01450214